Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Traditional Chinese medicine granule formula (spleen-invigorating, phlegm-resolving, blood-stasis-dissipating) is a botanical therapeutic developed by The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine. It is intended for the treatment of acute coronary syndrome (ACS), including unstable angina and non-ST elevation myocardial infarction (NSTEMI), particularly in patients diagnosed with the TCM pattern of thoracic obstruction characterized by phlegm turbidity and spleen deficiency. The formula aims to improve cardiac function and clinical outcomes by addressing the underlying TCM etiologies of spleen dysfunction, phlegm accumulation, and blood stasis. It is typically evaluated as an adjunctive therapy to standard Western medical care in prospective cohort studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on traditional Chinese medicine granule formula (spleen-invigorating, phlegm-resolving, blood-stasis-dissipating).